[go: up one dir, main page]

WO2002000165A3 - Agent for reversal of drug resistance in mycobacterium tuberculosis - Google Patents

Agent for reversal of drug resistance in mycobacterium tuberculosis Download PDF

Info

Publication number
WO2002000165A3
WO2002000165A3 PCT/IB2001/001136 IB0101136W WO0200165A3 WO 2002000165 A3 WO2002000165 A3 WO 2002000165A3 IB 0101136 W IB0101136 W IB 0101136W WO 0200165 A3 WO0200165 A3 WO 0200165A3
Authority
WO
WIPO (PCT)
Prior art keywords
inh
resistance
isoniazid
present
tuberculous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2001/001136
Other languages
French (fr)
Other versions
WO2002000165A2 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BAKULESH MAFATLAL KHAMAR
Original Assignee
BAKULESH MAFATLAL KHAMAR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BAKULESH MAFATLAL KHAMAR filed Critical BAKULESH MAFATLAL KHAMAR
Priority to APAP/P/2002/002454A priority Critical patent/AP2002002454A0/en
Priority to AU66257/01A priority patent/AU6625701A/en
Priority to EA200200290A priority patent/EA004875B1/en
Publication of WO2002000165A2 publication Critical patent/WO2002000165A2/en
Publication of WO2002000165A3 publication Critical patent/WO2002000165A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Multidrug resistance to anti-tuberculous drugs poses threat in the treatment of tuberculosis. These strains are resistant to at least two first line anti-tuberculous drugs such as INH and rifampicin. Frequently, such MDR strains show resistance to all commonly used first-line agent i.e. INH, rifamcpicin, streptomycin, ethambutol and pyrazinamide. Isoniazid is the most widely used anti-tuberculous drug. Resistance to isoniazid can occur by increased expression in inhA or by mutations that lower the enzyme's affinity to NADH. Mutations in katG, which encodes catalase peroxidase, is the most common source of resistance. Another mechanism of isoniazid resistance occurs by defects in NADH dehydrogenase (Ndh) of the respiratory chain. Increases expression of AphC has been suggested as another mechanism of INH resistance in mycobacteria. The present invention overcomes INH resistance by the use of penicillins with INH. According to present invention, penicillins when used in effective amount, reduces the MIC of INH in multi-drug resistant strains of M. tuberculosis. The improved INH sensitivity, as brought by the present invention, falls within the range which can be exploited for effective therapeutic intervention.
PCT/IB2001/001136 2000-06-28 2001-06-26 Agent for reversal of drug resistance in mycobacterium tuberculosis Ceased WO2002000165A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
APAP/P/2002/002454A AP2002002454A0 (en) 2000-06-28 2001-06-26 Agents for reversal of drug resistance in mycobacterium tuberculosis.
AU66257/01A AU6625701A (en) 2000-06-28 2001-06-26 Agent for reversal of drug resistance in mycobacterium tuberculosis
EA200200290A EA004875B1 (en) 2000-06-28 2001-06-26 Use an agent for reversal of drug resistance in mycobacterium tuberculosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN597/MUM/2000 2000-06-28
IN597MU2000 2000-06-28

Publications (2)

Publication Number Publication Date
WO2002000165A2 WO2002000165A2 (en) 2002-01-03
WO2002000165A3 true WO2002000165A3 (en) 2002-06-20

Family

ID=11097261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/001136 Ceased WO2002000165A2 (en) 2000-06-28 2001-06-26 Agent for reversal of drug resistance in mycobacterium tuberculosis

Country Status (4)

Country Link
AP (1) AP2002002454A0 (en)
AU (1) AU6625701A (en)
EA (1) EA004875B1 (en)
WO (1) WO2002000165A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP2042517B1 (en) 2002-09-27 2012-11-14 Xencor, Inc. Optimized FC variants and methods for their generation
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US7587286B2 (en) 2003-03-31 2009-09-08 Xencor, Inc. Methods for rational pegylation of proteins
JP2007512846A (en) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド Method for producing mutant protein having increased host string content and composition thereof
CA2561264A1 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
EP1919950A1 (en) 2004-07-15 2008-05-14 Xencor, Inc. Optimized fc variants
EP2325207B1 (en) 2004-11-12 2017-03-15 Xencor, Inc. FC variants with altered binding to FCRN
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
BR122021010656B1 (en) 2007-12-26 2022-07-19 Xencor, Inc ANTI-TNF ANTIBODY AND PHARMACEUTICAL COMPOSITION
CN101810610B (en) * 2010-04-19 2012-09-26 海南美兰史克制药有限公司 Amoxicillin sodium flucloxacillin sodium medicine compound liposome injection
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
EP2793944B1 (en) 2011-12-23 2025-10-08 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
CN109385439A (en) * 2018-09-18 2019-02-26 上海晶诺生物科技有限公司 The one recombination TM4 phage library and its application for constructing nadh dehydrogenase gene family missing mycobacterium tuberculosis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633131A (en) * 1992-04-30 1997-05-27 Institut Pasteur Rapid detection of isoniazid resistance in mycobacterium tuberculosis probes for selecting nucleic acid encoding isoniazid resistance, and methods and kits
US5686590A (en) * 1993-05-14 1997-11-11 Agresearch, New Zealand Pastoral Agriculture Research Institute Ltd. Methods and compositions for detecting and treating mycobacterial infections using an INHA gene
US5851763A (en) * 1992-09-17 1998-12-22 Institut Pasteur Rapid detection of antibiotic resistance in mycobacterium tuberculosis
US5871912A (en) * 1992-04-30 1999-02-16 Institut Pasteur Nucleic acid probes, sequences and methods for detecting mycobacterium tuberculosis resistant to isoniazid
US6200754B1 (en) * 1998-03-19 2001-03-13 Variagenics, Inc. Inhibitors of alternative alleles of genes encoding products that mediate cell response to environmental changes
US6329138B1 (en) * 1994-06-09 2001-12-11 Innogenetics, N.V. Method for detection of the antibiotic resistance spectrum of mycobacterium species

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633131A (en) * 1992-04-30 1997-05-27 Institut Pasteur Rapid detection of isoniazid resistance in mycobacterium tuberculosis probes for selecting nucleic acid encoding isoniazid resistance, and methods and kits
US5871912A (en) * 1992-04-30 1999-02-16 Institut Pasteur Nucleic acid probes, sequences and methods for detecting mycobacterium tuberculosis resistant to isoniazid
US6124098A (en) * 1992-04-30 2000-09-26 Institut Pasteur Rapid detection of antibiotic resistance in mycobacterium tuberculosis
US5851763A (en) * 1992-09-17 1998-12-22 Institut Pasteur Rapid detection of antibiotic resistance in mycobacterium tuberculosis
US5686590A (en) * 1993-05-14 1997-11-11 Agresearch, New Zealand Pastoral Agriculture Research Institute Ltd. Methods and compositions for detecting and treating mycobacterial infections using an INHA gene
US6329138B1 (en) * 1994-06-09 2001-12-11 Innogenetics, N.V. Method for detection of the antibiotic resistance spectrum of mycobacterium species
US6200754B1 (en) * 1998-03-19 2001-03-13 Variagenics, Inc. Inhibitors of alternative alleles of genes encoding products that mediate cell response to environmental changes

Also Published As

Publication number Publication date
AU6625701A (en) 2002-01-08
WO2002000165A2 (en) 2002-01-03
EA200200290A1 (en) 2002-12-26
EA004875B1 (en) 2004-08-26
AP2002002454A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
WO2002000165A3 (en) Agent for reversal of drug resistance in mycobacterium tuberculosis
Tracy et al. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil
Rodrıguez et al. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis
Aubry et al. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity
Viveiros et al. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines
Sisson et al. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori
Khoshnood et al. Mechanism of action, resistance, synergism, and clinical implications of delamanid against multidrug-resistant Mycobacterium tuberculosis
Ciofu et al. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center
Berning The role of fluoroquinolones in tuberculosis today
Burger et al. Pharmacokinetic interaction between rifampin and zidovudine
Karamanakos et al. Differentiation of disulfiram effects on central catecholamines and hepatic ethanol metabolism
MA29378B1 (en) PHARMACEUTICAL COMPOSITION COMPRISING OMEGA-CARBOXYARYL-SUBSTITUTED DIPHENYLUREE FOR THE TREATMENT OF CANCER
AU2003243545A1 (en) Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
Poirel et al. Integron-located oxa-32 gene cassette encoding an extended-spectrum variant of OXA-2 β-lactamase from Pseudomonas aeruginosa
Rodrigues-Junior et al. Activity of IQG-607, a new orally active compound, in a murine model of Mycobacterium tuberculosis infection
Tejedor et al. Mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from canine infections
Mechiche et al. Effects of cysteinyl leukotrienes in small human bronchus and antagonist activity of montelukast and its metabolites
WO2008008358A3 (en) Anti-cocaine compositions and treatment
CA2367615A1 (en) Transdermal therapeutic system with nicotine and addition of monoterpene ketones
Gadeau et al. Probable insensitivity of mollicutes to rifampin and characterization of spiroplasmal DNA-dependent RNA polymerase
WO2002000163A3 (en) The method of treating drug resistant mycobacterium tuberculosis infection
WO2000001720A3 (en) Compositions and methods for treating papillomavirus-infected cells
WO1996019578A3 (en) METHODS AND COMPOSITIONS FOR DETECTING AND TREATING MYCOBACTERIAL INFECTIONS USING AN ahpCF OPERON
Yong et al. The first detection of CTX-M-14 extended-spectrum β-lactamase among diverse β-lactamase–producing Proteus mirabilis clinical isolates
Shulgina Mechanisms of Mycobacterium tuberculosis Drug Resistance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IS JP KP KR LC LK LR LT LV MA MG MN MX NO NZ PL RO SG SK TT UA US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200200290

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2002 2002107448

Country of ref document: RU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IS JP KP KR LC LK LR LT LV MA MG MN MX NO NZ PL RO SG SK TT UA US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP